

Friday 7 March 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Monday 27 January 2025. I am pleased to confirm the following.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 44 (includes patients on abemaciclib and tamoxifen)
- Abemaciclib + Fulvestrant =2
- Alpelisib + Fulvestrant= 2
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide= 31
- Aromatase Inhibitor as a single agent- pharmacy can not access this data from pharmacy records
- Atezolizumab
- Capecitabine as a single agent=26
- Carboplatin + Paclitaxel= 1
- Elacestrant=0
- Eribulin as a single agent or in combination=2
- Everolimus + Exemestane=2
- Fulvestrant as a single agent=0
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)=15
- Palbociclib + Fulvestrant=2
- Parp Inhibitors (Olaparib/Talazoparib)= 2
- Pembrolizumab-0
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)-1
- Phesgo (Pertuzumab + Trastuzumab in a single injection)-35
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)-54
- Ribociclib + Fulvestrant-6
- Sacituzumab Govitecan-0
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent -8
- Trastuzumab deruxtecan (Enhertu)=3
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel-28
- Trastuzumab emtansine (Kadcyla)=5
- Any other active systemic anti-cancer therapy- Taxane in combination with platinum =5, gemcitabine carboplatin = 1, nreatinib =4, tucatinib in combination with capecitabine and trastuzumab= 1 , vinorelbine=1

Q2. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab emtansine (Kadcyla)

Under section 12(1) of the FOIA, MKUH is not obliged to comply with an information request where to do so would exceed the appropriate limit. We estimate that the cost of locating and collating any relevant information and extracting the information to meet your request would exceed the appropriate limit of £450 specified in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. We are therefore unable to comply with it. The £450 limit is based on work being carried out at a rate of £25 per hour, which equates to 18 hours of work per request. The cost of locating, retrieving and extracting information can be included in the costs for these purposes.

Task	Estimated Time (Hours)	Total Cost (£)
Determine if the information is held	4 hours	£100
Locate the information	4 hours	£100
Retrieve the information	6 hours	£150
Extract relevant information	6 hours	£150
Total Time	20 hours	£500

If you would like to revise your request, we will happily investigate it for you.

Q3. If breast cancer is not treated at or within the Trust, where are patients referred ?

Breast cancer is treated within MKUH.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.